AngioDynamics, Inc. (ANGO) Covered Calls

AngioDynamics, Inc. (ANGO) is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and vascular disease. In 2026, the company is successfully executing a strategic pivot toward its high-growth, high-margin "MedTech" segment, which includes its Auryon, NanoKnife, and Mechanical Thrombectomy platforms.

You can sell covered calls on AngioDynamics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ANGO (prices last updated Wed 12:20 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

AngioDynamics (ANGO) operates two primary segments: MedTech and Med Device. As of April 2026, the company is fundamentally reshaping its business mix, with MedTech now accounting for nearly 50% of total revenue. Key 2026 drivers include the Auryon peripheral atherectomy system and the AlphaVac mechanical thrombectomy platform, which saw a 47% revenue surge in the most recent quarter. The company’s NanoKnife system is also expanding, having recently received expanded European indications for multi-organ tumor ablation.

In its Q3 2026 earnings report (April 2, 2026), AngioDynamics beat expectations with $78.4 million in revenue and a narrower-than-expected loss. Despite facing 2026 macroeconomic headwinds—specifically a $6 million annual tariff impact and rising raw material costs—management raised its full-year guidance, supported by strong hospital utilization of its thrombus management tools and the launch of the LIVER-IRE Global Registry.

Competitive Landscape

AngioDynamics competes in the specialized interventional medicine market. It differentiates itself through its "Technosphere" of minimally invasive tools that offer alternatives to more invasive surgical procedures. In the options market, ANGO is a volatile small-cap medical stock that often sees activity tied to clinical trial data and FDA 510(k) clearances.

1. AtriCure, Inc.: A major peer in the medical device space focusing on minimally invasive treatments for atrial fibrillation and related conditions.
2. Integra LifeSciences Holdings Corporation: A diversified medical technology peer that competes in the surgical and regenerative tissue markets.
3. Alphatec Holdings, Inc.: A high-growth medical tech peer focusing on innovative spine surgery solutions.
4. Globus Medical, Inc.: A leading peer in the musculoskeletal and imaging space with high option liquidity.
5. GE HealthCare Technologies Inc.: While much larger, it serves as a valuation and technology benchmark for the imaging and interventional markets AngioDynamics serves.

Strategic Outlook and Innovation

The 2026 outlook for AngioDynamics is centered on "Clinical Validation and Market Expansion." The company is currently enrolling patients in the APEX-Return study for its AlphaVac system and recently received FDA IDE approval for the PAVE study. These trials are critical for expanding the company’s indications into pulmonary embolism and infective endocarditis treatment.

Innovation at ANGO is increasingly focused on procedural efficiency and reimbursement. The implementation of a new Category 1 CPT Code for prostate tissue ablation in January 2026 has significantly improved the economics for physicians using NanoKnife. With a debt-free balance sheet and approximately $38 million in cash, AngioDynamics is positioned to navigate 2026’s inflationary pressures while continuing to capture share in the $5 billion vascular and oncology intervention markets.

Want more examples? ANGL Covered Calls | ANIK Covered Calls